A VC fund based in the USA invests in many sectors, including cloud based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm invests in Series A and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.
The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, The firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.
The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm Invests in Therapeutics, Devices, and Diagnostics in USA & Canada, Investing Openly in All Clinical Stages of Development
A venture capital firm based in Canada is making seed and venture investments and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm prefers to lead financing rounds of Canadian companies and co-lead investments based in the United States.
The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway.
The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA Investment Firm Seeks Technologies with AI/Machine Learning Components, Primarily Investing in Software-Based Companies
An investment firm with offices in the USA invests in companies of all sectors that have some AI/ML component. Within healthcare, the firm invests in revenue-generating companies. The firm will not invest in any company that requires FDA approval. The firm invests primarily in the US, but reserves about 30% of their fund for investments in India. The firm invests in Series A and later companies, and will invest $0.5-2M per company.
The firm does not invest in therapeutics or medical devices, anything that requires FDA approval. The firm primarily invests in software-based companies, as long as the technology has an AI/ML component. This could include enterprise software, diagnostic image analysis or drug discovery platforms, as long as the therapeutics are then out-licensed, and not developed in house.
The firm can lead or co-invest, and will take a board or observer seat for larger check sizes. The firm is an active investor, and looks for management teams that are open to suggestion and are willing to benefit from the expertise of the firm and their network. The firm looks for companies that have at least $1M in ARR.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: PE Firm Seeks Late-Stage Assets and Devices Close to Market Approval That Have Strong China Market Potential, Investing As Much As $20M
A private equity firm with offices in Asia makes late venture and growth stage investments exclusively in the life sciences. The firm has raised 3 funds to date. The firm recently raised its third fund of USD 200 million in April 2014. The firm’s target investment size is USD 15-20 million per company and typically USD 5 million for cross-border investments. The firm primarily focuses on opportunities in China; however the firm is also interested in companies abroad that have a strong China angle or China strategy in near term (target market, R&D/manufacturing, sales, etc). The firm is actively seeking new investment opportunities.
The firm seeks to invest in late-stage assets that are on market or close to commercialization. The firm is interested in therapeutics/pharmaceuticals, medical devices, diagnostics, and healthcare services. For therapeutics, the firm will consider small molecules and biologics as well as biosimilars and reformulated drugs. At minimum, the product should be in Phase III of clinical trials. The firm may look at Phase II candidates that have a relatively less complicated clinical trial. For example, the firm will not consider biologics in Phase II. For indications, the firm focuses on products that address a large unmet medical need in China. This includes diabetes, cardiovascular, cerebrovascular, liver, and degenerative diseases. For medical devices, the firm is opportunistic in terms of subsectors. Similar to therapeutics, the firm focuses on indications relevant to China. The firm looks for devices that are very close to market or market approved.
The firm is only interested in companies that have a strong China angle or strategy. The firm typically seeks board representation post-investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot AI Mandate: US-based VC Invests in Software-based Companies with AI/ML Components in All Sectors
A venture capital firm based in Denver, Colorado and Dallas, Texas invests in companies of all sectors that have some AI/ML component. Within healthcare, the firm invests in revenue-generating companies. The firm will not invest in any company that requires FDA approval. The firm is currently investing out of their second $30M, with a third, $100M, to come soon. The firm invests primarily in the US, but reserves about 30% of their fund for investments in India. The firm invests in Series A and later companies, and will invest $0.5-2M per company.
The firm does not invest in therapeutics or medical devices, anything that requires FDA approval. The firm primarily invests in software-based companies, as long as the technology has an AI/ML component. This could include enterprise software, diagnostic image analysis or drug discovery platforms, as long as the therapeutics are then out-licensed, and not developed in house.
The firm can lead or co-invest, and will take a board or observer seat for larger check sizes. The firm is an active investor, and looks for management teams that are open to suggestion and are willing to benefit from the expertise of the firm and their network. The firm looks for companies that have at least $1M in ARR.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Hot AI Mandate: US & China-based PE with Multiple Funds Invests in Healthcare Companies of All Stages
Founded in 1996 and has offices in Palo Alto, CA, Shanghai, Beijing, Hongkong, Taipei, a PE firm is currently making investments from its three funds to healthcare companies of different stages, including pre-revenue, early-stage companies, post-revenue private companies and public companies. The firm invests exclusively in the healthcare sector; the firm invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative products in recent years there; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $20-50m, though larger investments are of interest as well; the innovation fund makes investments of typically $5-20 million. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.
The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area that the firm is interested and exploring. The firm’s innovation fund focuses on early-stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.
The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Hot AI Mandate: Venture Arm of Australia-based Infection Prevention Company Makes Strategic Investments into Digital Health, Diagnostics and Medical Devices
The corporate venture arm of an Australian-based company specializing in infection prevention technology, primarily in the hospital setting is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products into the market. Within the area of infection prevention and control, the firm will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm will invest globally.
The firm has a focus on digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare-acquired infection.
The firm will only make strategic investments that align with the corporate’s core business. The firm is an active investor, and will typically take a board seat after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
